RA CAPITAL MANAGEMENT, L.P.

Average Profitability
<0.0001%
Insider Buys Quantity
150
Insider Buys Sum
$1.89B
Insider Sells Quantity
71
Insider Sells Sum
$214.98M

Insider Activity of RA CAPITAL MANAGEMENT, L.P.

According to the SEC Form 4 filings, RA CAPITAL MANAGEMENT, L.P., being in a position of

  1. at 89bio, Inc.,
    оver the last 12 months, has bought 5714285 shares for $50M, and sold 0 shares,
    over all time since 2019-11-11, has bought 17307674 shares for $264.16M, and sold 0 shares.

The largest purchase of all time was on 2020-07-14 and amounted to 6666666 shares of Nkarta, Inc. for $120M.

The largest sale of all time was on 2021-03-11 and amounted to 710000 shares of Phathom Pharmaceuticals, Inc. for $31.06M.

Biography of RA CAPITAL MANAGEMENT, L.P.

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$200,922,965990
Sells
$3,807,102110

Comparison of Insiders on Amount of Buys and Sells

2025-03-13PurchaseMineralys Therapeutics, Inc.
MLYS
director
1.3M
2.6011%
$13.50$17.5M+17.89%
2025-03-07PurchaseJanux Therapeutics, Inc.
JANX
110,206
0.187%
$31.02$3.42M-0.36%
2025-03-06PurchaseJanux Therapeutics, Inc.
JANX
372,093
0.6366%
$30.78$11.45M-0.86%
2025-03-05PurchaseJanux Therapeutics, Inc.
JANX
341,742
0.5742%
$30.64$10.47M-3.05%
2025-01-30Purchase89bio, Inc.
ETNB
5.71M
4.871%
$8.75$50M-6.07%
2024-11-08PurchaseTyra Biosciences, Inc.
TYRA
1.22M
2.3305%
$16.25$19.84M-10.34%
2024-10-18PurchaseJanux Therapeutics, Inc.
JANX
1.2M
2.0576%
$44.75$53.7M-9.63%
2024-09-16PurchaseBicara Therapeutics Inc. Common Stock
BCAX
1.83M
2.6517%
$18.00$32.99M-30.78%
2024-08-09SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
3.53M
7.6298%
$1.08$3.81M+9.71%
2024-06-17PurchaseAerovate Therapeutics, Inc.
AVTE
928,110
0.2418%
$1.67$1.55M+46.67%
2024-03-27PurchaseNkarta, Inc.
NKTX
3M
5.4767%
$10.00$30M-58.16%
2024-03-27PurchaseARS Pharmaceuticals, Inc.
SPRY
505,954
0.3513%
$9.79$4.95M+15.66%
2024-03-26PurchaseARS Pharmaceuticals, Inc.
SPRY
457,745
0.31%
$9.55$4.37M+14.8%
2024-03-25PurchaseARS Pharmaceuticals, Inc.
SPRY
437,600
0.2811%
$9.06$3.96M+25.36%
2024-03-04Purchase89bio, Inc.
ETNB
1.35M
1.6718%
$15.35$20.72M-37.8%
2024-02-09PurchasePepGen Inc.
PEPG
2.56M
10.4935%
$10.64$27.21M-33.63%
2024-01-11PurchaseSolid Biosciences Inc.
SLDB
904,160
3.235%
$5.53$5M+1.75%
2023-12-11PurchaseWave Life Sciences Ltd.
WVE
1M
1.2134%
$5.00$5M+40.63%
2023-09-21PurchaseARS Pharmaceuticals, Inc.
SPRY
director
2.7M
0.5803%
$3.03$8.18M+131.88%
2023-08-29PurchaseARS Pharmaceuticals, Inc.
SPRY
director
3.75M
1.6487%
$6.20$23.25M+14.03%
Total: 221
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.